November 6, 2012

TG Therapeutics, Inc. to Participate in the Brean Capital 2012 Life Sciences Summit

NEW YORK, Nov. 6, 2012 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (OTCBB:TGTX), an innovative, clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of innovative and medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs, today announced that Michael Weiss, the Company's Executive Chairman and Interim Chief Executive Officer, will participate in the Brean Capital 2012 Life Sciences Summit held on Wednesday November 7, 2012 at the Sentry Centers in New York City. This conference will feature small group sessions as well as one on one meetings with institutional clients.

ABOUT TG THERAPEUTICS, INC.

TG Therapeutics is an innovative, clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of innovative and medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. Currently, the company is developing two advanced therapies targeting hematological malignancies. TGTX-1101 (ublituximab) is a novel, third generation monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes, currently in clinical development for patients with relapsed and refractory non-Hodgkin's lymphoma. TG Therapeutics is also developing TGR-1202, a highly specific, orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B‑lymphocytes. TG Therapeutics is headquartered in New York City.

The TG Therapeutics logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=11857

TGTX - G

```
CONTACT: Jenna Bosco

         Director - Investor Relations

         TG Therapeutics, Inc.

         Telephone: 212.554.4484

         Email: ir@tgtxinc.com
```


Source: TG Therapeutics, Inc.

News Provided by Acquire Media